Anti-FGF23 treatment was found to significantly improve the bone quality in CKD mice by correcting the secondary hyperparathyroidism, and increased calcitriol levels, indicating that FGF23 is a key factor of CKD related bone diseases. This evidence concerns the gene FGF23 and secondary hyperparathyroidism.